Skip to content
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
Archyde

Archyde

  • News
  • World
  • Economy
  • Technology
  • Health
  • Entertainment
  • Sport

hyperthyroidism

Satralizumab Sustains Proptosis Improvement in 85% of Responders With Thyroid Eye Disease at 48 Weeks

Satralizumab Sustains Proptosis Improvement in 85% of Responders With Thyroid Eye Disease at 48 Weeks

November 20, 2026 by Health Desk

Satralizumab (Enspryng) maintained reductions in eye bulging for roughly 85% of responders with thyroid eye disease through 48 weeks, according to pooled phase 3 data presented this week at the … Read More

Categories Health Tags clinical research, clinical studies, Clinical trials, eye, hyperthyroidism, Thyroid

Recent Posts

  • Slovakia Braces for Sharp Temperature Drop, First Snow and Double-Digit Frosts This Weekend
  • Satralizumab Sustains Proptosis Improvement in 85% of Responders With Thyroid Eye Disease at 48 Weeks
  • Sensor Tower Estimates GTA 6 Sold 24.5 Million Units, Hits $2.36bn Revenue
  • Austrian Chancellor Condemns Russian Strike on Kyiv Embassy
  • Three-Sport Athlete Endured 14-Year Delay Before Stage IV Endometriosis Excision Surgery
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
© 2026 Archyde — All Rights Reserved. Contact | Privacy Policy